NASDAQ:QTTB
Q32 Bio Inc.
Q32 Bio Inc.'s revenue was $53.7M in fiscal 2025. Free cash flow was −$33.5M, −62.4% of revenue, and the diluted share count rose 27.5%.Summary generated from Q32 Bio Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$53.7M
Revenue growthn/a
Revenue, 5-yr CAGR+81.9%
Gross marginn/a
Operating margin31.5%
Net margin55.5%
ROICn/a
Return on equity125.1%
Debt / equityn/a
Free cash flow−$33.5M
FCF margin−62.4%
Share count change+27.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 34 | 3 | −7 | 0 | 54 |
| Operating income | −96 | −133 | −48 | −66 | 17 |
| Net income | −96 | −5 | −54 | −48 | 30 |
| Free cash flow | −112 | −115 | −19 | −68 | −34 |
Recent filings
- 8-KRegulation FD disclosure
Sep 30, 2026 - 8-KRegulation FD disclosure
Sep 14, 2026 - 4Insider transaction report
Aug 27, 2026 - 4Insider transaction report
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KEntry into a material agreement
Jul 15, 2026 - 8-KOther events
Jul 13, 2026